Neurogen (NRGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Thomas M. who wrote (167)	5/7/1998 1:49:00 PM
From: phbolton	Read Replies (1) of 523

5/07 09:34 VECTOR SAYS STARTS TRANSKARYOTIC THERAPIES <TKTX.O>, NEUROGEN NRGN.O> AS BUY DEERFIELD, Ill., May 7 (Reuters) - Vector Securities analyst William Tanner said Thursday that he started coverage of Neurogen Corp. <NRGN.O> and Transkaryotic Therapies Inc. <TKTX.O> as buys. -- Both are development-stage biotechnology firms. -- Transkaryotic is developing a gene-activated version of erythropoietin for use in dialysis that could be launched in late 1999 or early 2000, Tanner said. -- Neurogen is developing drugs for neurological disorders,

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next